Every 10-Q that Viridian Therapeutics, Inc. (VRDN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.
Viridian Therapeutics is transitioning to a commercial-stage biopharma after U.S. approval of veligrotug, trade name Lumvoa, in June 2026 for thyroid eye disease. The company is also advancing elegrobart, a subcutaneous TED antibody, a thyroid stimulating hormone receptor program, and FcRn inhibitors VRDN-006 and VRDN-008.
For the three months ended June 30, 2026, total revenue was modest and primarily from license and collaboration fees, while research and development expense was $71,577 (in thousands) and selling, general and administrative expense was $54,975 (in thousands), leading to continued net losses. For the first half of 2026, the net loss reached $232,020 (in thousands), reflecting heavy investment in development and commercialization.
Liquidity remains strong, with $981.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, which management expects to fund planned operations for at least twelve months. In 2026 the company issued $250.0 million of 1.75% convertible senior notes due 2032 and completed a $143.8 million common stock offering, then repaid its Hercules term loan. Non-dilutive funding includes a revenue participation arrangement with DRI that generated a $75.0 million milestone on veligrotug approval but carries a 27.4% effective interest rate and future U.S. sales-based royalties. Accumulated deficit was $1,570.5 million, underscoring reliance on external capital and eventual product uptake.
Viridian Therapeutics reported a net loss of $104.9 million for the three months ended March 31, 2026, as it continues investing heavily in late‑stage development of therapies for serious and rare diseases. Revenue remained minimal at $0.1 million, while research and development expenses were $77.6 million and selling, general and administrative expenses were $38.7 million, reflecting clinical programs and commercial readiness efforts.
The company is advancing two IGF‑1R antibodies for thyroid eye disease. Veligrotug, an intravenous therapy, has positive phase 3 data in both active and chronic disease, and its biologics license application is under FDA Priority Review with a target action date of June 30, 2026. Subcutaneous elegrobart showed statistically significant proptosis responses in two phase 3 REVEAL trials, and Viridian plans a future BLA submission. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $762.2 million, which management believes will fund planned operations for at least 12 months.
Viridian Therapeutics reported a sharper top line in its Q3 2025 10-Q driven by license activity. Total revenue reached $70.6 million, including $70.0 million of license revenue. The company posted a net loss of $34.6 million, improving from a loss of $76.7 million a year ago, as higher revenue offset increased operating costs. Research and development expense was $86.3 million, and general and administrative expense was $24.3 million in the quarter.
Liquidity remains strong. Cash, cash equivalents and short-term investments totaled $490.9 million as of September 30, 2025, which management states should fund planned operations for at least twelve months. Year to date, net cash used in operating activities was $252.6 million, partly offset by $301.9 million net cash provided by investing activities and $20.8 million from financing. Long-term debt stood at $20.9 million, and in October 2025 the company extended its loan maturity to October 2030. Common shares outstanding were 95,442,008 as of October 31, 2025.